DRESS syndrome induced by meropenem

Prados-Castaño, M; Piñero-Saavedra, Macarena; Leguísamo-Milla, S.; Ortega-Camarero, M.A.; Vega-Rioja, A.

doi:10.1016/j.aller.2013.12.004

Cited by 13 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its broad spectrum coverage makes it a very attractive option in treating resistant organisms particularly P. aeruginosa . Meropenem has been linked to DRESS syndrome in one patient[ 14 ] and hypersensitivity syndrome along with Imipenem in an immunocompromised patient. [ 15 ] Cutaneous manifestations dominated the picture in both cases; drug-induced EP was not described nor suspected, and neither patient underwent bronchoscopic evaluation.…”

Section: Discussionmentioning

confidence: 99%

Meropenem: A possible new culprit in eosinophilic lung diseases

Hatem¹,

Campbell²,

Rubio³

et al. 2017

Lung India

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Meropenem: A possible new culprit in eosinophilic lung diseases

Hatem¹,

Campbell²,

Rubio³

et al. 2017

Lung India

View full text Add to dashboard Cite

“…There are isolated reports of positive patch test reactions to various dilutions of meropenem, including: meropenem 10% pet. in a patient with DRESS, confirmed with a lymphocyte activation test; and meropenem 5% pet. in a nurse with occupational contact dermatitis .…”

Section: Discussionmentioning

confidence: 78%

Patch testing with meropenem following a severe cutaneous adverse drug reaction

et al. 2018

View full text Add to dashboard Cite

K E Y W O R D S : allergic contact dermatitis, case report, cutaneous adverse drug reactions, DRESS, meropenem, patch testing, vancomycin Identifying the causative agent in cutaneous adverse drug reactions (CADRs) is often challenging when multiple drugs are involved. Patch testing is useful in some cases, but only a limited number of drugs are commercially available as diagnostic reagents, and for others there is often little information on sensitivity, optimum test concentrations, and vehicle. CASE REPORTA 57-year-old woman underwent a meningioma resection, which was complicated by postoperative sepsis. She then developed spiking temperatures, a widespread morbilliform rash, raised eosinophils and an increased alanine aminotransferase level 25 days after commencing phenytoin and 4 days after starting intravenous meropenem and vancomycin. This was consistent with drug reaction, eosinophilia, and systemic symptoms (DRESS) syndrome. The patient's rash also flared after she received intravenous contrast media for computed tomography. She was treated with systemic steroids, and the putative drugs were withdrawn.A lymphocyte proliferation test with phenytoin gave a negative result, but an interferon-γ release assay (ELIspot) gave a positive result, indicating delayed drug hypersensitivity. The patient had delayed reactions at 24 hours to several radiocontrast media (Omnipaque 1:100, Visipaque 1:100, and Neopam 1:100) on intradermal (ID) testing, whereas ID testing with meropenem gave a negative result. She proceeded to an intravenous meropenem drug challenge, and developed facial angioedema and a non-urticarial rash over her chest 12-18 hours later. There was a questionable/irritant reaction to vancomycin on ID testing, and there were no reactions to other β-lactam antibiotics. As these test results were unclear, the patient was then referred for patch testing.Patch testing was carried out with a shortened CADR series (Chemotechnique Diagnostics, Vellinge, Sweden). Meropenem and NICHOLSON ET AL. 397

show abstract

“…There have been several cases of meropenem or linezolid-induced DRESS. [45] However, the onset of the disease generally ranges from 2 to 8 weeks after the initiation of therapy. In our case, meropenem and linezolid were used no more than 2 days before the onset of the disease.…”

Section: Discussionmentioning

confidence: 99%

Drug reaction with eosinophilia and systemic symptom in a patient with pneumonia and hyperthyroidism

Jin¹,

Wang²,

Ye³

2017

J Res Pharm Pract

View full text Add to dashboard Cite

Drug rash with eosinophilia and systemic symptoms syndrome is an idiosyncratic drug reaction characterized by fever, skin eruption, lymph node enlargement, and internal organ involvement. We report a case of a patient with pneumonia who developed clinical manifestations of fever, rash, lymphadenopathy, hypereosinophilia, and visceral involvement (renal failure and eosinophilic pneumonitis) caused by methimazole. The patient improved remarkably with drug withdrawal. A high index of clinical suspicion is emphasized to facilitate prompt diagnosis of medication-related adverse effect and its discontinuation.

show abstract

DRESS syndrome induced by meropenem

Cited by 13 publications

References 7 publications

Meropenem: A possible new culprit in eosinophilic lung diseases

Meropenem: A possible new culprit in eosinophilic lung diseases

Patch testing with meropenem following a severe cutaneous adverse drug reaction

Drug reaction with eosinophilia and systemic symptom in a patient with pneumonia and hyperthyroidism

Contact Info

Product

Resources

About